Temperature control plaster based on external vesicles, preparation method and application

By employing a layered structure and external vesicle technology, the shortcomings of traditional Chinese medicine plasters in terms of active ingredient extraction, transdermal drug delivery, and temperature control have been overcome. This has enabled the efficient extraction and stable delivery of tanshinone, providing rapid anti-inflammatory and long-lasting repair effects for osteoarthritis.

CN120859988APending Publication Date: 2025-10-31GUANGDONG JUFUKANG BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202510978396.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-07-16
Publication Date
2025-10-31

AI Technical Summary

Technical Problem

Traditional Chinese medicine plasters have many problems in terms of active ingredient extraction, transdermal drug delivery, temperature control, and therapeutic effects, including degradation of heat-sensitive ingredients, difficulty in penetrating the stratum corneum, large temperature fluctuations, short drug action time, and insufficient targeting.

Method used

The temperature-controlled medicated plaster adopts a layered structure, including a backing layer, a heating layer, an isolation layer, and a drug layer. It utilizes a temperature-controlled and heating composition of iron powder, activated carbon, sodium chloride, and vermiculite powder, combined with a microporous PE membrane and porous starch microspheres, to load tanshinone-Panax notoginseng exovesicles. The exovesicles are extracted by polyethylene glycol precipitation, ensuring the stability and targeted delivery of active ingredients.

Benefits of technology

It achieves efficient extraction and preservation of tanshinone, stable control of drug layer temperature, and prolongs drug action time, providing a dual therapeutic effect of rapid anti-inflammation and long-term repair, and has significant efficacy for bone and joint diseases such as cervical spondylosis and lumbar disc herniation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
Patent Text Reader

Abstract

The invention relates to the technical field of crossing of traditional Chinese medicine transdermal preparations and medical instruments, in particular to a temperature control plaster based on external vesicles, a preparation method and application, and the temperature control plaster based on the external vesicles comprises the following layered structures from outside to inside: a backing layer, a heating layer, an isolation layer and a medicine layer, the method has the beneficial effects that the salvia miltiorrhiza-pseudo-ginseng external vesicles are efficiently extracted through a polyethylene glycol precipitation method, and the extraction efficiency and the active ingredient preservation rate are high; external vesicles are prevented from being damaged by high temperature through a layered temperature control structure, and the temperature of a medicine layer is stabilized in an optimal treatment range; the outer vesicles are slowly released through the porous starch microsphere carrier, so that stable slow release and targeted delivery of the medicine are realized, and the action time is prolonged; through the synergistic effect of the external vesicles and the traditional Chinese medicine active ingredients, a dual treatment mechanism of rapid anti-inflammation and long-acting repair is established, targeted treatment of cervical spondylosis, lumbar disc herniation and other osteoarticular diseases is achieved, and the external vesicles have multiple effects of resisting inflammation, easing pain, promoting tissue repair, improving microcirculation and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of cross-disciplinary technology of transdermal preparations of traditional Chinese medicine and medical devices, specifically to a temperature-controlled plaster based on external vesicles, its preparation method, and its application. Background Technology

[0002] Traditional Chinese medicine plasters have the following technical shortcomings in clinical application:

[0003] 1. In terms of active ingredient extraction technology, conventional high-temperature processing can easily lead to the degradation of heat-sensitive components such as tanshinone and notoginsenosides, and it is difficult to effectively extract plant vesicles with targeted therapeutic effects.

[0004] 2. Regarding transdermal drug delivery systems, large molecular active ingredients have difficulty penetrating the stratum corneum barrier, and existing carrier systems have difficulty maintaining drug stability.

[0005] 3. In terms of temperature control, conventional heating systems experience large temperature fluctuations, which is not conducive to the stable release of heat-sensitive components;

[0006] 4. In terms of treatment efficacy, existing products have problems such as short drug action time and insufficient targeting. Summary of the Invention

[0007] To overcome the technical deficiencies in the prior art and effectively solve the technical problems in the background art, the present invention provides the following technical solution:

[0008] A temperature-controlled medicated plaster based on exovesicles, the temperature-controlled medicated plaster based on exovesicles includes the following layered structure from the outside to the inside: a backing layer, a heating layer, an insulating layer and a drug layer;

[0009] The backing layer is a breathable non-woven fabric;

[0010] The heating layer is a temperature-controlled heating composition made of iron powder, activated carbon, sodium chloride and vermiculite powder mixed evenly in a certain proportion;

[0011] The isolation layer is a microporous PE membrane, which is a polymer film with a uniform microporous structure. It is made of polyethylene material through physical or chemical methods to form a controllable micron-level pore structure.

[0012] The drug layer is a mixture of porous starch microspheres loaded with Danshen-Sanqi exovesicles and Sanqi-Danshen powder;

[0013] The external vesicles were extracted using a polyethylene glycol precipitation method, with an activity retention rate >85%.

[0014] As a preferred embodiment of the present invention, the mass percentage of each component in the heating layer is: 50-70% iron powder, 10-20% activated carbon, 5-10% sodium chloride, and 5-15% vermiculite powder, and its constant temperature range is 35-40℃.

[0015] As a preferred embodiment of the present invention, the microporous PE membrane of the isolation layer has a pore size of 5-20 μm.

[0016] As a preferred embodiment of the present invention, in the drug layer: the outer vesicle particle size is 50-200 nm; the porous starch microsphere pore size is 50-300 nm; the mass ratio of porous starch microspheres to outer vesicles is 1:1 to 1:5; the outer vesicle loading rate is ≥60%; the particle size of Panax notoginseng-Salvia miltiorrhiza powder is 800-1000 mesh; and the porosity of porous starch microspheres is 60-80%.

[0017] As a preferred embodiment of the present invention, a far-infrared ceramic powder layer is further provided between the heating layer and the insulating layer, wherein the far-infrared ceramic powder has a particle size of 1-5μm and a radiation wavelength of 8-12μm.

[0018] As a preferred embodiment of the present invention, the thickness of the breathable nonwoven fabric of the backing layer is 0.15-0.25 mm.

[0019] A method for preparing a temperature-controlled medicated plaster based on exovesicles includes the following steps:

[0020] S1: Extraction of external vesicles;

[0021] S2: Mix the outer vesicles with porous starch microspheres in a certain proportion, and then mix them with Panax notoginseng and Salvia miltiorrhiza powder;

[0022] S3: Assemble the backing layer, heating layer, isolation layer and drug layer in sequence;

[0023] S4: Package the finished product to obtain the temperature-controlled plaster based on exovesicles.

[0024] As a preferred embodiment of the present invention, the method for extracting the external vesicles includes the following steps:

[0025] a. Pretreatment: Take the tissues of Salvia miltiorrhiza and Panax notoginseng, wash them with phosphate buffer, grind them into homogenates, add phosphate buffer to suspend them, and obtain crude extract;

[0026] b. Centrifugation to remove impurities: Centrifuge the crude extract at 3000×g and 4℃ for 15 minutes, and collect the supernatant; then centrifuge at 10,000×g and 4℃ for 20 minutes, and collect the supernatant.

[0027] c. Polyethylene glycol precipitation: Add polyethylene glycol 6000 (10% w / v final concentration) and NaCl (0.15M final concentration) to the supernatant obtained in step b, mix gently at 4°C and let stand for 3 hours;

[0028] d. Centrifugal purification: Centrifuge the mixture obtained in step c at 12,000×g and 4℃ for 30 minutes, discard the supernatant, resuspend the precipitate in phosphate buffer, centrifuge again at 12,000×g and 4℃ for 30 minutes, discard the supernatant, and finally resuspend the precipitate in phosphate buffer to obtain the outer vesicles.

[0029] As a preferred technical solution of the present invention, the method for preserving the extracted vesicles is to dry the extracted vesicles into powder and then freeze-dry them for preservation.

[0030] An application of the plaster prepared by the aforementioned method: the temperature-controlled plaster based on exovesicles is used for the treatment of osteoarthritis.

[0031] Compared with the prior art, the beneficial effects of the present invention are:

[0032] 1. The polyethylene glycol precipitation method can efficiently extract the exovesicles of Tanshinone and Panax notoginseng, retaining active ingredients (such as tanshinone), which significantly improves the extraction efficiency and the retention rate of active ingredients;

[0033] 2. Through a layered temperature control structure (heating layer + isolation layer), high temperatures are avoided from damaging the outer vesicles, ensuring that the temperature of the drug layer remains stable within the optimal treatment range;

[0034] 3. Through the use of porous starch microspheres with specific pore sizes as carriers for sustained-release exovesicles, stable sustained-release and targeted delivery of drugs are achieved, extending the duration of action;

[0035] 4. Through the synergistic effect of external vesicles and active ingredients of traditional Chinese medicine, a dual treatment mechanism of "rapid anti-inflammatory and long-term repair" has been established, realizing targeted treatment of musculoskeletal diseases such as cervical spondylosis and lumbar disc herniation, and also has multiple effects such as anti-inflammatory and analgesic, promoting tissue repair and improving microcirculation. Detailed Implementation

[0036] To make the objectives, technical solutions, and advantages of this invention clearer, the technical solutions in the embodiments of this invention will be described more clearly and completely below. Obviously, the described embodiments are only some embodiments of this invention, and not all embodiments. Based on the embodiments of this invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of this invention.

[0037] This invention provides a technical solution: a temperature-controlled plaster based on external vesicles, which comprises the following layered structure from the outside to the inside: a backing layer, a heating layer, an insulating layer, and a drug layer;

[0038] The backing layer is made of breathable non-woven fabric with a thickness of 0.15-0.25mm;

[0039] The heating layer is a temperature-controlled heating composition made of iron powder, activated carbon, sodium chloride and vermiculite powder mixed evenly in a certain proportion. The mass percentage of each component is: iron powder 50-70%, activated carbon 10-20%, sodium chloride 5-10%, vermiculite powder 5-15%. Its constant temperature range is 35-40℃. Its preparation and operation principle are existing mature technologies and will not be described further here.

[0040] The isolation layer is a microporous PE membrane with a pore size of 5-20μm;

[0041] The drug layer is a mixture of porous starch microspheres loaded with Danshen-Sanqi exovesicles and Sanqi-Danshen powder;

[0042] Among them, the exovesicles were extracted by polyethylene glycol precipitation, with an activity retention rate >85%; the exovesicle particle size was 50-200 nm; the porous starch microspheres had a pore size of 50-300 nm; the mass ratio of porous starch microspheres to exovesicles was 1:1 to 1:5; the exovesicle loading rate was ≥60%; the particle size of the Panax notoginseng-Salvia miltiorrhiza powder was 800-1000 mesh; and the porosity of the porous starch microspheres was 60-80%.

[0043] Furthermore, a far-infrared ceramic powder layer is provided between the heating layer and the insulating layer. The far-infrared ceramic powder has a particle size of 1-5μm and a radiation wavelength of 8-12μm.

[0044] A method for preparing a temperature-controlled medicated plaster based on exovesicles includes the following steps:

[0045] S1: Extraction of external vesicles, the specific extraction method is as follows:

[0046] a. Pretreatment: Take the tissues of Salvia miltiorrhiza and Panax notoginseng, wash them with phosphate buffer, grind them into homogenates, add phosphate buffer to suspend them, and obtain crude extract;

[0047] b. Centrifugation to remove impurities: Centrifuge the crude extract at 3000×g and 4℃ for 15 minutes, and collect the supernatant; then centrifuge at 10,000×g and 4℃ for 20 minutes, and collect the supernatant.

[0048] c. Polyethylene glycol precipitation: Add polyethylene glycol 6000 (10% w / v final concentration) and NaCl (0.15M final concentration) to the supernatant obtained in step b, mix gently at 4°C and let stand for 3 hours;

[0049] d. Centrifugal purification: Centrifuge the mixture obtained in step c at 12,000×g and 4℃ for 30 minutes, discard the supernatant, resuspend the precipitate in phosphate buffer, centrifuge again at 12,000×g and 4℃ for 30 minutes, discard the supernatant, and finally resuspend the precipitate in phosphate buffer to obtain the outer vesicles.

[0050] e. Preservation method of external vesicles: Dry the extracted external vesicles into powder and then freeze-dry them (external vesicles are not easy to preserve). When using, simply sprinkle the freeze-dried powder of external vesicles onto the plaster.

[0051] S2: Mix the outer vesicles with porous starch microspheres in a certain proportion, and then mix them with Panax notoginseng and Salvia miltiorrhiza powder;

[0052] S3: The backing layer, heating layer, isolation layer and drug layer are assembled in sequence. The operating principle is a mature existing technology and will not be described in detail here.

[0053] S4: By packaging the finished product using existing conventional technology, the temperature-controlled plaster based on the exovesicle can be obtained.

[0054] An application of a medicated plaster prepared by a method for treating osteoarthritis using an external vesicle-based temperature-controlled medicated plaster.

[0055] Experimental Example 1:

[0056] I. Extraction and Detection of Exovesicles

[0057] 1. Extraction of external vesicles:

[0058] a. Pretreatment: Take the tissues of Salvia miltiorrhiza and Panax notoginseng, wash them with phosphate buffer, grind them into homogenates, add phosphate buffer to suspend them, and obtain crude extract;

[0059] b. Centrifugation to remove impurities: Centrifuge the crude extract at 3000×g and 4℃ for 15 minutes, and collect the supernatant; then centrifuge at 10,000×g and 4℃ for 20 minutes, and collect the supernatant.

[0060] c. Polyethylene glycol precipitation: Add polyethylene glycol 6000 (10% w / v final concentration) and NaCl (0.15M final concentration) to the supernatant obtained in step b, mix gently at 4°C and let stand for 3 hours;

[0061] d. Centrifugal purification: Centrifuge the mixture obtained in step c at 12,000×g and 4℃ for 30 minutes, discard the supernatant, resuspend the precipitate in phosphate buffer, centrifuge again at 12,000×g and 4℃ for 30 minutes, discard the supernatant, and finally resuspend the precipitate in phosphate buffer to obtain the outer vesicles.

[0062] 2. Test Results:

[0063] Particle size distribution: The particle size distribution of the outer vesicles was determined by nanoparticle tracking analysis, and the results showed that they were mainly distributed in the range of 50-200 nm.

[0064] Biomarker content: Enzyme-linked immunosorbent assay (ELISA) was used to detect extravesicular biomarkers. The results showed that the CD63 positivity rate was >95% and the tanshinone IIA content was ≥60 ng / mg protein.

[0065] II. Structural Design Verification

[0066] 1. Temperature control test: The heating layer was stably heated in the air for 8 hours, and the temperature of the drug layer was maintained at 37±2℃ (detected by infrared thermal imager).

[0067] 2. Transdermal test: The transdermal test was conducted using a Franz Diffusion Cell. The results showed that the transdermal rate of the porous starch microsphere-loaded exoves reached 45% after 24 hours, which was significantly higher than that of the free exoves group (15%).

[0068] Partial clinical case reports:

[0069] 1. Case 1 (lumbar disc herniation):

[0070] Patient: Male, 50 years old, with a disease duration of 3 years. The pain level of the patient was assessed using the Visual Analogue Scale (VAS), and the pain score was 7.5.

[0071] Treatment: Apply the patch to the lumbar pain point for 6 hours daily for 14 consecutive days;

[0072] Results: Pain score decreased to 2.0, and MRI showed reduced intervertebral disc edema.

[0073] 2. Case 2 (Cervical spondylosis):

[0074] Patient: Female, 48 years old, with neck and shoulder pain accompanied by dizziness;

[0075] Treatment: Apply the plaster to the Dazhui acupoint for 8 hours daily;

[0076] Results: Dizziness disappeared after 7 days, and cervical spine mobility improved by 60% after 14 days.

[0077] Some of the theoretical basis of this invention:

[0078] 1. Synergistic effect of Danshen and Panax notoginseng:

[0079] The active ingredient tanshinone in Danshen (Salvia miltiorrhiza) inhibits intervertebral disc inflammation by blocking the NF-κB pathway, reducing the production of inflammatory factors interleukin-6 and tumor necrosis factor-α. The active ingredient notoginseng saponins in Panax notoginseng activate the colA1 gene, promoting collagen synthesis by chondrocytes and repairing the intervertebral disc matrix. The synergistic effect of these two ingredients provides both anti-inflammatory and repairing benefits, achieving a therapeutic effect on intervertebral disc degeneration.

[0080] 2. Advantages of external vesicles:

[0081] Natural nanocarriers with strong skin barrier penetration ability; protect contents from degradation.

[0082] Comparison of therapeutic efficacy data:

[0083]

[0084] Advantages compared to traditional medicated plasters:

[0085]

[0086] Note: * indicates a significant difference (p<0.05).

[0087] in conclusion:

[0088] Rapid onset of action: The average pain relief time is 38.8±15.2 minutes (traditional plasters take about 60 minutes or more).

[0089] Highly effective pain relief: VAS score decreased by an average of 68.2±12.4% (compared to about 40-50% for traditional medicated plasters).

[0090] High comfort level: The patient comfort score reached 4.3±0.7 points (compared to 3.1±0.9 points for traditional medicated plasters).

[0091] Although embodiments of the invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions and alterations can be made to these embodiments without departing from the principles and spirit of the invention, the scope of which is defined by the appended claims and their equivalents.

Claims

1. A temperature-controlled medicated plaster based on exovesicles, characterized in that: The temperature-controlled plaster based on external vesicles comprises the following layered structure from the outside to the inside: a backing layer, a heating layer, an insulating layer, and a drug layer; The backing layer is a breathable non-woven fabric; The heating layer is a temperature-controlled heating composition made of iron powder, activated carbon, sodium chloride and vermiculite powder mixed evenly in a certain proportion; The isolation layer is a microporous PE membrane; The drug layer is a mixture of porous starch microspheres loaded with Danshen-Sanqi exovesicles and Sanqi-Danshen powder; The external vesicles were extracted using a polyethylene glycol precipitation method, with an activity retention rate >85%.

2. The temperature-controlled plaster based on exovesicles according to claim 1, characterized in that: The heating layer contains the following components by mass percentage: 50-70% iron powder, 10-20% activated carbon, 5-10% sodium chloride, and 5-15% vermiculite powder, with a constant temperature range of 35-40℃.

3. The temperature-controlled plaster based on exovesicles according to claim 1, characterized in that: The microporous PE membrane of the isolation layer has a pore size of 5-20 μm.

4. The temperature-controlled plaster based on exovesicles according to claim 1, characterized in that: In the drug layer: the outer vesicle particle size is 50-200 nm; the porous starch microsphere pore size is 50-300 nm; the mass ratio of porous starch microspheres to outer vesicles is 1:1 to 1:5; the outer vesicle loading rate is ≥60%; the particle size of Panax notoginseng-Salvia miltiorrhiza powder is 800-1000 mesh; and the porosity of porous starch microspheres is 60-80%.

5. The temperature-controlled plaster based on exovesicles according to claim 1, characterized in that: A far-infrared ceramic powder layer is also provided between the heating layer and the insulating layer. The far-infrared ceramic powder has a particle size of 1-5μm and a radiation wavelength of 8-12μm.

6. The temperature-controlled plaster based on exovesicles according to claim 1, characterized in that: The thickness of the breathable nonwoven fabric of the backing layer is 0.15-0.25 mm.

7. The method for preparing the temperature-controlled plaster based on exovesicles according to any one of claims 1-6, characterized in that: Includes the following steps: S1: Extraction of external vesicles; S2: Mix the outer vesicles with porous starch microspheres in a certain proportion, and then mix them with Panax notoginseng and Salvia miltiorrhiza powder; S3: Assemble the backing layer, heating layer, isolation layer and drug layer in sequence; S4: Package the finished product to obtain the temperature-controlled plaster based on exovesicles.

8. The method for preparing the temperature-controlled plaster based on exovesicles according to claim 7, characterized in that: The method for extracting the external vesicles includes the following steps: a. Pretreatment: Take the tissues of Salvia miltiorrhiza and Panax notoginseng, wash them with phosphate buffer, grind them into homogenates, add phosphate buffer to suspend them, and obtain crude extract; b. Centrifugation to remove impurities: Centrifuge the crude extract at 3000×g and 4℃ for 15 minutes, and collect the supernatant; then centrifuge at 10,000×g and 4℃ for 20 minutes, and collect the supernatant. c. Polyethylene glycol precipitation: Add polyethylene glycol 6000 (10% w / v final concentration) and NaCl (0.15M final concentration) to the supernatant obtained in step b, mix gently at 4°C and let stand for 3 hours; d. Centrifugal purification: Centrifuge the mixture obtained in step c at 12,000×g and 4℃ for 30 minutes, discard the supernatant, resuspend the precipitate in phosphate buffer, centrifuge again at 12,000×g and 4℃ for 30 minutes, discard the supernatant, and finally resuspend the precipitate in phosphate buffer to obtain the outer vesicles.

9. The method for preparing the temperature-controlled plaster based on exovesicles according to claim 8, characterized in that: The method for preserving the extracted vesicles is as follows: the extracted vesicles are dried into powder and then freeze-dried for preservation.

10. The application of the plaster prepared according to the method of claim 9, characterized in that: The prepared temperature-controlled plaster based on external vesicles is used for the treatment of osteoarthritis.